Compare AbCellera Biologics Inc (ABCL) vs Alphabet Inc Class A (GOOGL) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Alphabet (GOOGL) trades at $358.85, down 2.08% today, with a bullish technical outlook supported by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $5.11 versus $2.64 expected. Revenue grew to $402.84 billion in 2025, with net income margins expanding to 32.8%. Analyst consensus remains overwhelmingly positive, with 85% buy ratings and a $431.35 price target.

GOOGL presents a compelling growth story driven by AI integration and cloud expansion, though regulatory scrutiny and competitive pressures pose risks. The stock's valuation at 28 times earnings is justified by robust profitability and cash flow generation. Upside potential exists if execution continues, but investors should monitor antitrust developments and tech sector volatility.